- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
Patent holdings for IPC class C07D 401/04
Total number of patents in this class: 12139
10-year publication summary
|
783
|
790
|
774
|
763
|
743
|
724
|
774
|
711
|
613
|
67
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4795 |
267 |
| Novartis AG | 10494 |
196 |
| Celgene Corporation | 1392 |
164 |
| Merck Patent GmbH | 5727 |
153 |
| F. Hoffmann-La Roche AG | 7893 |
148 |
| Boehringer Ingelheim International GmbH | 4595 |
135 |
| Vertex Pharmaceuticals Incorporated | 1624 |
115 |
| Hoffmann-La Roche Inc. | 3602 |
114 |
| Janssen Pharmaceutica N.V. | 3340 |
111 |
| BASF SE | 21135 |
109 |
| Merck Sharp & Dohme LLC | 3751 |
107 |
| Bayer AG | 3409 |
104 |
| Takeda Pharmaceutical Company Limited | 2710 |
100 |
| Syngenta Crop Protection AG | 6335 |
99 |
| Gilead Sciences, Inc. | 2134 |
92 |
| Pfizer Inc. | 3384 |
90 |
| AstraZeneca AB | 2833 |
87 |
| FMC Corporation | 820 |
85 |
| Sumitomo Chemical Company, Limited | 9039 |
82 |
| Dana-Farber Cancer Institute, Inc. | 2640 |
82 |
| Other owners | 9699 |